The recent acquisition of Gigamoto Technology Partners (W. Conshohocken, PA) expands United BioSource Corporation's (Bethesda, MD) leadership in drug safety, the company says. The purchase is UBC's second of the year and provides the company with several risk management programs, including the largest and longest running FDA-mandated program: iPLEDGE, an interactive computer-based distribution center that monitors pregnancy in women on Accutane.
“Managing drug safety for increasingly complex drugs and biologicals requires world class scientific expertise, strong operations, and demands state of the art technology,” said Ethan Leder, Chief Executive Officer of United Biosource. “The acquisition of Gigamoto enhances and accelerates our technology platform to include more top-notch FDA approved technology solutions for complex post-approval programs."
The full press release is available here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.